GeneCentric Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-06-20.
GeneCentric Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on June 20, 2025. The filing reports $2M sold. Its industry group is Biotechnology. It names MICHAEL MILBURN (Executive Officer, Director), CLAY THORP (Director), ARNOLD LEVINE (Director) (SEC Form D, June 20, 2025).
Is this your company?
Sell to companies like GeneCentric Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-06-20 · the record
Pitching, partnering or investing alongside them? See who really runs and owns GeneCentric Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind GeneCentric Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in North Carolina, filed within 90 days of this one, largest first.
Get an email when GeneCentric Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when GeneCentric Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch GeneCentric Therapeutics, Inc. →Get the full cited report on GeneCentric Therapeutics, Inc.
What the filing shows about GeneCentric Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on GeneCentric Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives GeneCentric Therapeutics, Inc.'s address as 100 Capitola Drive, Suite 275, Durham, NC 27713.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on GeneCentric Therapeutics, Inc. See pricing
GeneCentric Therapeutics, Inc. is a registered filer with the SEC (CIK 1529224) and has filed since 2025-06-20. 1 filing is on record, the latest on 2025-06-20.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
GeneCentric Therapeutics, Inc.'s Form D of 2025-06-20 names MICHAEL MILBURN, CLAY THORP, ARNOLD LEVINE and 4 more as its officers, directors or promoters.
Its new offerings report $2M sold across 1 offering, as its own filings state.
Trailing twelve months. 769 filings in Biotechnology, totalled by week.
Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.
Michael Milburn is named as Executive Officer and Director on the Form D that GeneCentric Therapeutics, Inc. filed with the SEC on 20 June 2025, one of 7 people that filing names.
Clay Thorp is named as Director on the Form D that GeneCentric Therapeutics, Inc. filed with the SEC on 20 June 2025, one of 7 people that filing names.
Arnold Levine is named as Director on the Form D that GeneCentric Therapeutics, Inc. filed with the SEC on 20 June 2025, one of 7 people that filing names.
Myla Lai-Goldman is named as Director on the Form D that GeneCentric Therapeutics, Inc. filed with the SEC on 20 June 2025, one of 7 people that filing names.
Charles Perou is named as Director on the Form D that GeneCentric Therapeutics, Inc. filed with the SEC on 20 June 2025, one of 7 people that filing names.
Don Hardison is named as Director on the Form D that GeneCentric Therapeutics, Inc. filed with the SEC on 20 June 2025, one of 7 people that filing names.
Prasanth Reddy is named as Director on the Form D that GeneCentric Therapeutics, Inc. filed with the SEC on 20 June 2025, one of 7 people that filing names.
7 people named on the filing — 1 holding an executive role and 6 as directors only.
Named as of the 2025-06-20 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about GeneCentric Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on GeneCentric Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on GeneCentric Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist GeneCentric Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind GeneCentric Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for GeneCentric Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Raleigh-Durham
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/genecentric-therapeutics-inc-form-d-25000001